Best practices in diagnostic immunohistochemistry: Pleomorphic cutaneous spindle cell tumors

Archives of Pathology and Laboratory Medicine

Volumn 131, Issue 10, 2007, Pages 1517-1524

  Folpe, Andrew L ^a   Cooper, Kumarasen ^b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF VERMONT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; CD34 ANTIGEN; CD68 ANTIGEN; CYTOKERATIN; DESMIN; MELAN A; PROTEIN HMB 45; PROTEIN S 100; SMOOTH MUSCLE ACTIN; TRANSCRIPTION FACTOR FLI 1; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ANTIGEN DETECTION; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; ENDOTHELIUM CELL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PLEOMORPHIC CUTANEOUS SPINDLE CELL TUMOR; PROTEIN DETERMINATION; REVIEW; SKIN TUMOR; SMOOTH MUSCLE FIBER; SPINDLE CELL CARCINOMA; STAINING;

CARCINOMA, SQUAMOUS CELL; DIAGNOSIS, DIFFERENTIAL; HISTIOCYTOMA, MALIGNANT FIBROUS; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; SARCOMA; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; XANTHOMATOSIS;

EID: 35348986559     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Taylor CR. Immunomicroscopy: A Diagnostic Tool for the Surgical Pathologist. Philadelphia, Pa: Saunders; 1986:xviii, 452, [2] of plates.
2. Reis-Filho JS, Simpson PT, Martins A, Preto A, Gartner F, Schmitt FC. Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virchows Arch. 2003;443:122-132.
3. Lin L, Skacel M, Sigel JE, et al. Epithelioid sarcoma: an immunohistochemical analysis evaluating the utility of cytokeratin 5/6 in distinguishing superficial epithelioid sarcoma from spindled squamous cell carcinoma. J Cutan Pathol. 2003;30:114-117.
4. Sigel JE, Skacel M, Bergfeld WF, House NS, Rabkin MS, Goldblum JR. The utility of cytokeratin 5/6 in the recognition of cutaneous spindle cell squamous cell carcinoma. J Cutan Pathol. 2001;28:520-524.
5. Akhtar M, Tulbah A, Kardar AH, Ali MA. Sarcomatoid renal cell carcinoma: the chromophobe connection. Am J Surg Pathol. 1997;21:1188-1195.
6. Eckert F, de Viragh PA, Schmid U. Coexpression of cytokeratin and vimentin intermediate filaments in benign and malignant sweat gland tumors. J Cutan Pathol. 1994;21:140-150.
7. Lopez-Beltran A, Escudero AL, Cavazzana AO, Spagnoli LG, Vicioso-Recio L. Sarcomatoid transitional cell carcinoma of the renal pelvis: a report of five cases with clinical, pathological, immunohistochemicaland DNA ploidy analysis. Pathol Res Pract. 1996;192:1218-1224.
8. Meis JM, Ordonez NG, Gallager HS. Sarcomatoid carcinoma of the breast: an immunohistochemical study of six cases. Virchows Arch A Pathol Anat Histopathol. 1987;410:415-421.
9. Skalli O, Gabbiani G, Babai F, Seemayer TA, Pizzolato G, Schurch W. Intermediate filament proteins and actin isoforms as markers for soft tissue tumor differentiation and origin, II: rhabdomyosarcomas. Am J Pathol. 1988;130:515-531.
10. Azumi N, Battifora H. The distribution of vimentin and keratin in epithelial and nonepithelial neoplasms: a comprehensive immunohistochemical study on formalin- and alcohol-fixed tumors. Am J Clin Pathol. 1987;88:286-296.
11. Nakajima T, Watanabe S, Sato Y, Kameya T, Shimosato Y. Immunohistochemical demonstration of S100 protein in human malignant melanoma and pigmented nevi. Gann. 1981;72:335-336.
12. Nakajima T, Watanabe S, Sato Y, Kameya T, Shimosato Y, Ishihara K. Immunohistochemical demonstration of S100 protein in malignant melanoma and pigmented nevus, and its diagnostic application. Cancer. 1982;50:912-918.
13. Weiss SW, Langloss JM, Enzinger FM. Value of S-100 protein in the diagnosis of soft tissue tumors with particular reference to benign and malignant Schwann cell tumors. Lab Invest. 1983;49:299-308.
14. Gown AM, Vogel AM, Hoak D, Gough F, McNutt MA. Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes. Am J Pathol. 1986;123:195-203.
15. Pea M, Martignoni G, Zamboni G, Bonetti F. Perivascular epithelioid cell [letter; comment]. Am J Surg Pathol. 1996;20:1149-1153.
16. Pea M, Martignoni G, Bonetti F, et al. Tumors characterized by the presence of HMB45-positive perivascular epithelioid cell (PEC) - a novel entity in surgical pathology. Electron J Pathol Histol. 1997;3:28-40.
17. Folpe AL, Mentzel T, Lehr HA, Fisher C, Balzer BL, Weiss SW. Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature. Am J Surg Pathol. 2005;29:1558-1575.
18. Longacre TA, Egbert BM, Rouse RV. Desmoplastic and spindle-cell malignant melanoma: an immunohistochemical study. Am J Surg Pathol. 1996;20:1489-1500.
19. Kaufmann O, Koch S, Burghardt J, Audring H, Dietel M. Tyrosinase, melan-A, and KBA62 as markers for the immunohistochemical identification of metastatic amelanotic melanomas on paraffin sections. Mod Pathol. 1998;11:740-746.
20. Busam KJ, Chen YT, Old LJ, et al. Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma. Am J Surg Pathol. 1998;22:976-982.
21. Busam KJ, Jungbluth AA. Melan-A, a new melanocytic differentiation marker. Adv Anat Pathol. 1999;6:12-18.
22. Busam KJ, Iversen K, Coplan KA, et al. Immunoreactivity for A103, an antibody to melan-A (Mart-1), in adrenocortical and other steroid tumors [see comments]. Am J Surg Pathol. 1998;22:57-63.
23. Jungbluth AA, Busam KJ, Gerald WL, et al. A103: an anti-melan-a monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues [see comments]. Am J Surg Pathol. 1998;22:595-602.
24. Koch MB, Shih IM, Weiss SW, Folpe AL. Microphthalmia transcription factor and melanoma cell adhesion molecule expression distinguish desmoplastic/ spindle cell melanoma from morphologic mimics. Am J Surg Pathol. 2001;25:58-64.
25. Zavala-Pompa A, Folpe AL, Jimenez RE, et al. Immunohistochemical study of microphthalmia transcription factor and tyrosinase in angiomyolipoma of the kidney, renal cell carcinoma, and renal and retroperitoneal sarcomas: comparative evaluation with traditional diagnostic markers. Am J Surg Pathol. 2001;25:65-70.
26. Hofbauer GF, Kamarashev J, Geertsen R, Boni R, Dummer R. Tyrosinase immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution. J Cutan Pathol. 1998;25:204-209.
27. De Young BR, Frierson HF Jr, Ly MN, Smith D, Swanson PE. CD31 immunoreactivity in carcinomas and mesotheliomas. Am J Clin Pathol. 1998;110:374-377.
28. Miettinen M, Lindenmayer AE, Chaubal A. Endothelial cell markers CD31, CD34, and BNH9 antibody to H- and Y-antigens - evaluation of their specificity and sensitivity in the diagnosis of vascular tumors and comparison with von Willebrand factor. Mod Pathol. 1994;7:82-90.
29. Rizzo M, SivaSai KS, Smith MA, et al. Increased expression of inflammatory cytokines and adhesion molecules by alveolar macrophages of human lung allograft recipients with acute rejection: decline with resolution of rejection. J Heart Lung Transplant. 2000;19:858-865.
30. McKenney JK, Weiss SW, Folpe AL. CD31 expression in intratumoral macrophages: a potential diagnostic pitfall. Am J Surg Pathol. 2001;25:1167-1173.
31. van de Rijn M, Rouse R. CD34: a review. Appl Immunohistochem. 1994; 2:71-80.
32. Folpe AL, Veikkola T, Valtola R, Weiss SW. Vascular endothelial growth factor receptor-3 (VEGFR-3): a marker of vascular tumors with presumed lymphatic differentiation, including Kaposi's sarcoma, kaposiform and Dabska-type hemangioendotheliomas, and a subset of angiosarcomas. Mod Pathol. 2000;13:180-185.
33. Hammock L, Reisenauer A, Wang W, Cohen C, Birdsong G, Folpe AL. Latency-associated nuclear antigen expression and human herpesvirus-8 polymerase chain reaction in the evaluation of Kaposi sarcoma and other vascular tumors in HIV-positive patients. Mod Pathol. 2005;18:463-468.
34. Miettinen M, Fanburg-Smith JC, Virolainen M, Shmookler BM, Fetsch JF. Epithelioid sarcoma: an immunohistochemical analysis of 112 classical and variant cases and a discussion of the differential diagnosis. Hum Pathol. 1999;30:934-942.
35. Sirgi KE, Wick MR, Swanson PE. B72.3 and CD34 immunoreactivity in malignant epithelioid soft tissue tumors: adjuncts in the recognition of endothelial neoplasms. Am J Surg Pathol. 1993;17:179-185.
36. Laskin WB, Miettinen M. Epithelioid sarcoma: new insights based on an extended immunohistochemical analysis. Arch Pathol Lab Med. 2003;127:1161-1168.
37. Folpe AL, Chand EM, Goldblum JR, Weiss SW. Expression of Fli-1, a nuclear transcription factor, distinguishes vascular neoplasms from potential mimics. Am J Surg Pathol. 2001;25:1061-1066.
38. Rossi S, Orvieto E, Furlanetto A, Laurino L, Ninfo V, Dei Tos AP. Utility of the immunohistochemical detection of FLI-1 expression in round cell and vascular neoplasm using a monoclonal antibody. Mod Pathol. 2004;17:547-552.
39. Burgdorf WH, Mukai K, Rosai J. Immunohistochemical identification of factor VIII-related antigen in endothelial cells of cutaneous lesions of alleged vascular nature. Am J Clin Pathol. 1981;75:167-171.
40. Lessard JL. Two monoclonal antibodies to actin: one muscle selective and one generally reactive. Cell Motil Cytoskeleton. 1988;10:349-362.
41. Skalli O, Ropraz P, Trzeciak A, Benzonana G, Gillessen D, Gabbiani G. A monoclonal antibody against alpha-smooth muscle actin: a new probe for smooth muscle differentiation. J Cell Biol. 1986;103:2787-2796.
42. Tsukada T, McNutt MA, Ross R, Gown AM. HHF35, a muscle actin-specific monoclonal antibody, II: reactivity in normal, reactive, and neoplastic human tissues. Am J Pathol. 1987;127:389-402.
43. Tsukada T, Tippens D, Gordon D, Ross R, Gown AM. HHF35, a muscle-actin-specific monoclonal antibody. I. Immunocytochemical and biochemical characterization. Am J Pathol. 1987;126:51-60.
44. Kindblom LG, Seidal T, Karlsson K. Immuno-histochemical localization of myoglobin in human muscle tissue and embryonal and alveolar rhabdomyosarcoma. Acta Pathol Microbiol Immunol Scand A Pathol. 1982;90:167-174.
45. Andriko JW, Kaldjian EP, Tsokos M, Abbondanzo SL, Jaffe ES. Reticulum cell neoplasms of lymph nodes: a clinicopathologic study of 11 cases with recognition of a new subtype derived from fibroblastic reticular cells. Am J Surg Pathol. 1998;22:1048-1058.
46. Cho J, Gong G, Choe G, Yu E, Lee I. Extrafollicular reticulum cells in pathologic lymph nodes. J Korean Med Sci. 1994;9:9-15.
47. Van Muijen GN, Ruiter DJ, Warnaar SO. Coexpression of intermediate filament polypeptides in human fetal and adult tissues. Lab Invest. 1987;57:359-369.
48. Franquemont DW, Frierson HF Jr, Mills SE. An immunohistochemical study of normal endometrial stroma and endometrial stromal neoplasms: evidence for smooth muscle differentiation. Am J Surg Pathol. 1991;15:861-870.
49. Parham DM, Dias P, Kelly DR, Rutledge JC, Houghton P. Desmin positivity in primitive neuroectodermal tumors of childhood. Am J Surg Pathol. 1992;16:483-492.
50. Folpe AL, Goldblum JR, Rubin BP, et al. Morphologic and immunophenotypic diversity in Ewing family tumors: a study of 66 genetically confirmed cases. Am J Surg Pathol. 2005;29:1025-1033.
51. Nikolaou I, Barbatis C, Laopodis V, Bekir S, Fletcher CD. Intra-abdominal desmoplastic small-cell tumours with divergent differentiation: report of two cases and review of the literature. Pathol Res Pract. 1992;188:981-988.
52. Gerald WL, Miller HK, Battifora H, Miettinen M, Silva EG, Rosai J. Intra-abdominal desmoplastic small round-cell tumor: report of 19 cases of a distinctive type of high-grade polyphenotypic malignancy affecting young individuals [see comments]. Am J Surg Pathol. 1991;15:499-513.
53. Ordonez NG. Desmoplastic small round cell tumor, II: an ultrastructural and immunohistochemical study with emphasis on new immunohistochemical markers. Am J Surg Pathol. 1998;22:1314-1327.
54. Sugimoto T, Ueyama H, Hosoi H, et al. Alpha-smooth-muscle actin and desmin expressions in human neuroblastoma cell lines. Int J Cancer. 1991;48:277-283.
55. Hurlimann J. Desmin and neural marker expression in mesothelial cells and mesotheliomas. Hum Pathol. 1994;25:753-757.
56. Folpe AL, Weiss SW, Fletcher CDM, Gown AM. Tenosynovial giant cell tumors: evidence for a desmin-positive dendritic cell subpopulation. Mod Pathol. 1998;11:939-944.
57. Folpe AL, Weiss SW. Ossifying fibromyxoid tumor of soft parts: a clinicopathologic study of 70 cases with emphasis on atypical and malignant variants. Am J Surg Pathol. 2003;27:421-431.
58. Fanburg-Smith JC, Miettinen M. Angiomatoid "malignant" fibrous histiocytoma: a clinicopathologic study of 158 cases and further exploration of the myoid phenotype. Hum Pathol. 1999;30:1336-1343.
59. Hasegawa T, Seki K, Ono K, Hirohashi S. Angiomatoid (malignant) fibrous histiocytoma: a peculiar low-grade tumor showing immunophenotypic heterogeneity and ultrastructural variations. Pathol Int. 2000;50:731-738.
60. Zarbo RJ, Gown AM, Nagle RB, Visscher DW, Crissman JD. Anomalous cytokeratin expression in malignant melanoma: one- and two-dimensional western blot analysis and immunohistochemical survey of 100 melanomas. Mod Pathol. 1990;3:494-501.
61. Holness CL, Simmons DL. Molecular cloning of CD68, a human macrophage marker related to lysosomal glycoproteins. Blood. 1993;81:1607-1613.
62. Cassidy M, Loftus B, Whelan A, et al. KP-1: not a specific marker: staining of 137 sarcomas, 48 lymphomas, 28 carcinomas, 7 malignant melanomas and 8 cystosarcoma phyllodes. Virchows Arch. 1994;424:635-640.
63. Smith ME, Costa MJ, Weiss SW. Evaluation of CD68 and other histiocytic antigens in angiomatoid malignant fibrous histiocytoma [see comments]. Am J Surg Pathol. 1991;15:757-763.
64. Dei Tos AP, Doglioni C, Laurino L, Fletcher CD. KP1 (CD68) expression in benign neural tumours: further evidence of its low specificity as a histiocytic/ myeloid marker. Histopathology. 1993;23:185-187.
65. Gloghini A, Rizzo A, Zanette I, et al. KP1/CD68 expression in malignant neoplasms including lymphomas, sarcomas, and carcinomas. Am J Clin Pathol. 1995;103:425-431.
66. Ben-Izhak O, Auslander L, Rabinson S, Lichtig C, Sternberg A. Epithelioid angiosarcoma of the adrenal gland with cytokeratin expression: report of a case with accompanying mesenteric fibromatosis. Cancer. 1992;69:1808-1812.
67. Gray MH, Rosenberg AE, Dickersin GR, Bhan AK. Cytokeratin expression in epithelioid vascular neoplasms. Hum Pathol. 1990;21:212-217.
68. O'Connell JX, Kattapuram SV, Mankin HJ, Bhan AK, Rosenberg AE. Epithelioid hemangioma of bone: a tumor often mistaken for low-grade angiosarcoma or malignant hemangioendothelioma [see comments]. Am J Surg Pathol. 1993;17:610-617.
69. van Haelst UJ, Pruszczynski M, ten Cate LN, Mravunac M. Ultrastructural and immunohistochemical study of epithelioid hemangioendothelioma of bone: coexpression of epithelial and endothelial markers. Ultrastruct Pathol. 1990;14: 141-149.
70. Wenig BM, Abbondanzo SL, Heffess CS. Epithelioid angiosarcoma of the adrenal glands: a clinicopathologic study of nine cases with a discussion of the implications of finding "epithelial-specific" markers. Am J Surg Pathol. 1994;18:62-73.
71. Miettinen M. Immunoreactivity for cytokeratin and epithelial membrane antigen in leiomyosarcoma. Arch Pathol Lab Med. 1988;112:637-640.
72. Ramaekers FC, Pruszczynski M, Smedts F. Cytokeratins in smooth muscle cells and smooth muscle tumours. Histopathology. 1988;12:558-561.
73. Tauchi K, Tsutsumi Y, Yoshimura S, Watanabe K. Immunohistochemical and immunoblotting detection of cytokeratin in smooth muscle tumors. Acta Pathol Jpn. 1990;40:574-580.
74. Weiss SW, Goldblum JR. Enzinger and Weiss's Soft Tissue Tumors. 4th ed. St Louis, Mo: Mosby; 2001:xiv, 1622.
75. Stevenson A, Chatten J, Bertoni F, Miettinen M. CD99 (p30/32MIC2) Neuroectodermal/Ewing's sarcoma antigen as an immunohistochemical marker: review of more than 600 tumors and the literature experience. Appl Immunohistochem. 1994;2:231-240.